- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Do-Coop Technologies Ltd., a privately held corporation based in Israel, introduces a new Solubilization Service to its expanding portfolio that utilizes NeowaterŪ, its proprietary water-based nanotechnology. This new service enables the solubilization of highly hydrophobic compounds with little to no traces of organic compounds, while not compromising bioavailability and functionality of the specific API.
Do-Coop Technologies Ltd., a privately held corporation based in Israel, announced today the commercial availability of NeowaterŪ - Solubilization Service, a new service that solvates customers' hydrophobic, insoluble molecules and drugs using Do-Coop's proprietary Neowater technology improving solubility and bioavailability.
Neowater is an enabling technology utilizing breakthrough water-based nanotechnology. Unlike traditional, dry nanotechnology, which focuses on a nanoparticle end product, Neowater builds upon the unique properties of nanoparticles to modify the physical properties of water molecules around them.
Each nanoparticle within Neowater, with its huge surface, creates an effect known as the "surface effect," and in turn organizes the water molecules surrounding it. This is similar to the surface effect of organelles within living cells. Both the organelles and the nanoparticles use this unique mechanism to create intracellular water. While the former is within cells and organs and cannot be harnessed nor used in a lab bench, the latter one, which is branded as Neowater, can.
This technology, developed in Israel, produces water whose physical properties mimic that of intracellular water using inorganic, insoluble crystals introduced in water in a patented process. Neowater, with its stable system of largely hydrated nanoparticles, like non-ionic detergent derived micelles, reduces the entropy of aqueous solutions. In addition, by design, it exhibits both hydrophilic and hydrophobic properties.
About NeowaterŪ - Solubilization Service
Biotech and pharmaceutical companies have within their portfolios a significant number of compounds and drugs, such as novel cancer therapeutics, which have been proven effective in vitro, yet they are very insoluble and thus unusable. While these companies are experts at screening and finding effective compounds, and they have invested millions in this effort, they often lack the expertise to overcome this challenging technological barrier and thus be able to market these compounds. Neowater technology dramatically enhances the stability and bioavailability of those compounds that are difficult-to-solvate, or that are can be dissolved with organic solvents but then exhibit poor bioavailability or have toxicity-related issues. Neowater enables companies to capture the real value of their otherwise valueless portfolios of unusable compounds.
"We are launching our new Neowater -- Solubilization Service as our response to requests from customers for us to help them overcome a very painful technological barrier and allow them to solvate their difficult-to-solvate, hydrophobic compounds without toxic organic solvents. We have designed the new Solubilization Service ( http://www.docoop.com/page_lev3.asp?page_id=155&page_id_2=195&topic=2 )(Cat. No. NW711) in such a way that it is simple to use, limiting the amount of information a customer needs to disclose to us, and providing a straightforward solution for customers to validate in their own labs. Besides a purchase order, all that is required from customers is to send to Do-Coop (a) a vial with a sufficient amount of their compound to solvate with Neowater, (b) information about the name or the type of solvents currently used to solvate the compound, and (c) a desired final end-use solution concentration using Neowater as the new solvent as well as any other requirements for the final solution. Within a matter of a few weeks we will provide back a sterile vial with the compound solvated in a solution with Neowater and less as possible organic solvents," said Eran Gabbai, founder, President and CTO of Do-Coop Technologies, and the inventor of Neowater technology.
"We have packaged our enabling technology capabilities into this unique, simple-to-use service that can reduce or replace polar solvents such as detergents, surfactants, alcohols and other broadly used solvents like DMSO. Using our new service, biotech and pharma companies can solvate their valuable compounds, enhancing both stability and bioavailability, and thus leverage their investments. Neowater is nontoxic, environmentally friendly, inexpensive, and can easily be integrated into existing and new drugs and allow for IPR extension. We anticipate that with this service launch many more biotech and pharma companies will be able to validate the performance of Neowater-solvated compounds in their own laboratory tests, and then return to us to license this unique capability," added Mr. Gabbai.
Do-Coop Technologies is also offering its customers the option of signing up for a turn-key Feasibility and Development Project that includes stability and bioavailability reports of the Neowater-solvated compound and a larger supply of it for customer testing.
An example of such service can be found here ( http://www.docoop.com/files/docoop_files/Fortuna%20Kohen%20Abstract.pdf )
About Do-Coop Technologies Ltd.
Do-Coop Technologies Ltd. is a private company based in Israel. Do-Coop was formed in 1997 in order to develop and commercialize novel water-based materials using Nanotechnology for the biotechnology, pharmaceutical and chemical industries and for additional industries as well.
For more information, please click here
Copyright © Do-Coop Technologies Ltd.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Programmable materials find strength in molecular repetition May 23rd, 2016
Electronic device detects molecules linked to cancer, Alzheimer's and Parkinson's: An inexpensive portable biosensor has been developed by researchers at Brazil's National Nanotechnology Laboratory with FAPESP's support May 20th, 2016